Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Identifieur interne : 002F44 ( PubMed/Checkpoint ); précédent : 002F43; suivant : 002F45Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Auteurs : Marc Peeters [Belgique] ; Kelly S. Oliner [États-Unis] ; Timothy J. Price [Australie] ; Andrés Cervantes [Espagne] ; Alberto F. Sobrero [Italie] ; Michel Ducreux [France] ; Yevhen Hotko [Ukraine] ; Thierry André [France] ; Emily Chan [États-Unis] ; Florian Lordick [Allemagne] ; Cornelis J A. Punt [Pays-Bas] ; Andrew H. Strickland [Australie] ; Gregory Wilson [Royaume-Uni] ; Tudor E. Ciuleanu [Roumanie] ; Laslo Roman [Russie] ; Eric Van Cutsem [Belgique] ; Pei He [États-Unis] ; Hua Yu [États-Unis] ; Reija Koukakis [Suisse] ; Jan-Henrik Terwey [Suisse] ; Andre S. Jung [États-Unis] ; Roger Sidhu [États-Unis] ; Scott D. Patterson [États-Unis]Source :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de mutations d'ADN, Analyse de survie, Anticorps monoclonaux (administration et posologie), Camptothécine (analogues et dérivés), Camptothécine (effets indésirables), Camptothécine (usage thérapeutique), Exons, Femelle, Fluorouracil (effets indésirables), Fluorouracil (usage thérapeutique), Gènes ras, Humains, Leucovorine (effets indésirables), Leucovorine (usage thérapeutique), Modèles de hasards proportionnels, Mutation, Mâle, Métastase tumorale, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines proto-oncogènes B-raf (génétique), Reprise du traitement, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs colorectales (anatomopathologie), Tumeurs colorectales (génétique), Tumeurs colorectales (mortalité), Tumeurs colorectales (traitement médicamenteux).
- MESH :
- administration et posologie : Anticorps monoclonaux.
- analogues et dérivés : Camptothécine.
- anatomopathologie : Tumeurs colorectales.
- effets indésirables : Camptothécine, Fluorouracil, Leucovorine, Protocoles de polychimiothérapie antinéoplasique.
- génétique : Protéines proto-oncogènes B-raf, Tumeurs colorectales.
- mortalité : Tumeurs colorectales.
- traitement médicamenteux : Tumeurs colorectales.
- usage thérapeutique : Camptothécine, Fluorouracil, Leucovorine, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Analyse de mutations d'ADN, Analyse de survie, Exons, Femelle, Gènes ras, Humains, Modèles de hasards proportionnels, Mutation, Mâle, Métastase tumorale, Reprise du traitement, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Camptothecin (adverse effects), Camptothecin (analogs & derivatives), Camptothecin (therapeutic use), Colorectal Neoplasms (drug therapy), Colorectal Neoplasms (genetics), Colorectal Neoplasms (mortality), Colorectal Neoplasms (pathology), DNA Mutational Analysis, Exons, Female, Fluorouracil (adverse effects), Fluorouracil (therapeutic use), Genes, ras, Humans, Leucovorin (adverse effects), Leucovorin (therapeutic use), Male, Middle Aged, Mutation, Neoplasm Metastasis, Proportional Hazards Models, Proto-Oncogene Proteins B-raf (genetics), Retreatment, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Fluorouracil, Leucovorin.
- chemical , analogs & derivatives : Camptothecin.
- drug therapy : Colorectal Neoplasms.
- genetics : Colorectal Neoplasms, Proto-Oncogene Proteins B-raf.
- mortality : Colorectal Neoplasms.
- pathology : Colorectal Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Fluorouracil, Leucovorin.
- Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Exons, Female, Genes, ras, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proportional Hazards Models, Retreatment, Survival Analysis, Treatment Outcome.
Abstract
We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).
DOI: 10.1158/1078-0432.CCR-15-0526
PubMed: 26341920
Affiliations:
- Allemagne, Australie, Belgique, Espagne, France, Italie, Pays-Bas, Roumanie, Royaume-Uni, Russie, Suisse, Ukraine, États-Unis
- Angleterre, Californie, District de Leipzig, Grand Manchester, Hollande-Septentrionale, Saxe (Land), Tennessee, Île-de-France
- Amsterdam, Leipzig, Manchester, Paris
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26341920Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</title>
<author><name sortKey="Peeters, Marc" sort="Peeters, Marc" uniqKey="Peeters M" first="Marc" last="Peeters">Marc Peeters</name>
<affiliation wicri:level="1"><nlm:affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Antwerp University Hospital and University of Antwerp, Edegem</wicri:regionArea>
<wicri:noRegion>Edegem</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Oliner, Kelly S" sort="Oliner, Kelly S" uniqKey="Oliner K" first="Kelly S" last="Oliner">Kelly S. Oliner</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Price, Timothy J" sort="Price, Timothy J" uniqKey="Price T" first="Timothy J" last="Price">Timothy J. Price</name>
<affiliation wicri:level="1"><nlm:affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queen Elizabeth Hospital and University of Adelaide, Woodville</wicri:regionArea>
<wicri:noRegion>Woodville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cervantes, Andres" sort="Cervantes, Andres" uniqKey="Cervantes A" first="Andrés" last="Cervantes">Andrés Cervantes</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Biomedical Research Institute INCLIVA, University of Valencia</wicri:regionArea>
<wicri:noRegion>University of Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sobrero, Alberto F" sort="Sobrero, Alberto F" uniqKey="Sobrero A" first="Alberto F" last="Sobrero">Alberto F. Sobrero</name>
<affiliation wicri:level="1"><nlm:affiliation>Ospedale San Martino, Genova, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ospedale San Martino, Genova</wicri:regionArea>
<wicri:noRegion>Genova</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ducreux, Michel" sort="Ducreux, Michel" uniqKey="Ducreux M" first="Michel" last="Ducreux">Michel Ducreux</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotko, Yevhen" sort="Hotko, Yevhen" uniqKey="Hotko Y" first="Yevhen" last="Hotko">Yevhen Hotko</name>
<affiliation wicri:level="1"><nlm:affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</nlm:affiliation>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Uzhgorod National University, Uzhgorod</wicri:regionArea>
<wicri:noRegion>Uzhgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, Emily" sort="Chan, Emily" uniqKey="Chan E" first="Emily" last="Chan">Emily Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vanderbilt University Medical Center, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lordick, Florian" sort="Lordick, Florian" uniqKey="Lordick F" first="Florian" last="Lordick">Florian Lordick</name>
<affiliation wicri:level="3"><nlm:affiliation>University Cancer Center, Leipzig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University Cancer Center, Leipzig</wicri:regionArea>
<placeName><region type="land" nuts="1">Saxe (Land)</region>
<region type="district" nuts="2">District de Leipzig</region>
<settlement type="city">Leipzig</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J A" last="Punt">Cornelis J A. Punt</name>
<affiliation wicri:level="3"><nlm:affiliation>Academic Medical Center, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strickland, Andrew H" sort="Strickland, Andrew H" uniqKey="Strickland A" first="Andrew H" last="Strickland">Andrew H. Strickland</name>
<affiliation wicri:level="1"><nlm:affiliation>Monash Medical Center, East Bentleigh, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Monash Medical Center, East Bentleigh</wicri:regionArea>
<wicri:noRegion>East Bentleigh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, Gregory" sort="Wilson, Gregory" uniqKey="Wilson G" first="Gregory" last="Wilson">Gregory Wilson</name>
<affiliation wicri:level="3"><nlm:affiliation>Christie Hospital, Manchester, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Christie Hospital, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ciuleanu, Tudor E" sort="Ciuleanu, Tudor E" uniqKey="Ciuleanu T" first="Tudor E" last="Ciuleanu">Tudor E. Ciuleanu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca</wicri:regionArea>
<wicri:noRegion>Cluj Napoca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Roman, Laslo" sort="Roman, Laslo" uniqKey="Roman L" first="Laslo" last="Roman">Laslo Roman</name>
<affiliation wicri:level="1"><nlm:affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Leningrad Regional Oncology Dispensary, Saint Petersburg</wicri:regionArea>
<wicri:noRegion>Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals and KU Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="He, Pei" sort="He, Pei" uniqKey="He P" first="Pei" last="He">Pei He</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Hua" sort="Yu, Hua" uniqKey="Yu H" first="Hua" last="Yu">Hua Yu</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koukakis, Reija" sort="Koukakis, Reija" uniqKey="Koukakis R" first="Reija" last="Koukakis">Reija Koukakis</name>
<affiliation wicri:level="1"><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea>
<wicri:noRegion>Zug</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Terwey, Jan Henrik" sort="Terwey, Jan Henrik" uniqKey="Terwey J" first="Jan-Henrik" last="Terwey">Jan-Henrik Terwey</name>
<affiliation wicri:level="1"><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea>
<wicri:noRegion>Zug</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jung, Andre S" sort="Jung, Andre S" uniqKey="Jung A" first="Andre S" last="Jung">Andre S. Jung</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sidhu, Roger" sort="Sidhu, Roger" uniqKey="Sidhu R" first="Roger" last="Sidhu">Roger Sidhu</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patterson, Scott D" sort="Patterson, Scott D" uniqKey="Patterson S" first="Scott D" last="Patterson">Scott D. Patterson</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26341920</idno>
<idno type="pmid">26341920</idno>
<idno type="doi">10.1158/1078-0432.CCR-15-0526</idno>
<idno type="wicri:Area/PubMed/Corpus">002625</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002625</idno>
<idno type="wicri:Area/PubMed/Curation">002556</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002556</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002556</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002556</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</title>
<author><name sortKey="Peeters, Marc" sort="Peeters, Marc" uniqKey="Peeters M" first="Marc" last="Peeters">Marc Peeters</name>
<affiliation wicri:level="1"><nlm:affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Antwerp University Hospital and University of Antwerp, Edegem</wicri:regionArea>
<wicri:noRegion>Edegem</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Oliner, Kelly S" sort="Oliner, Kelly S" uniqKey="Oliner K" first="Kelly S" last="Oliner">Kelly S. Oliner</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Price, Timothy J" sort="Price, Timothy J" uniqKey="Price T" first="Timothy J" last="Price">Timothy J. Price</name>
<affiliation wicri:level="1"><nlm:affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queen Elizabeth Hospital and University of Adelaide, Woodville</wicri:regionArea>
<wicri:noRegion>Woodville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cervantes, Andres" sort="Cervantes, Andres" uniqKey="Cervantes A" first="Andrés" last="Cervantes">Andrés Cervantes</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Biomedical Research Institute INCLIVA, University of Valencia</wicri:regionArea>
<wicri:noRegion>University of Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sobrero, Alberto F" sort="Sobrero, Alberto F" uniqKey="Sobrero A" first="Alberto F" last="Sobrero">Alberto F. Sobrero</name>
<affiliation wicri:level="1"><nlm:affiliation>Ospedale San Martino, Genova, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ospedale San Martino, Genova</wicri:regionArea>
<wicri:noRegion>Genova</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ducreux, Michel" sort="Ducreux, Michel" uniqKey="Ducreux M" first="Michel" last="Ducreux">Michel Ducreux</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotko, Yevhen" sort="Hotko, Yevhen" uniqKey="Hotko Y" first="Yevhen" last="Hotko">Yevhen Hotko</name>
<affiliation wicri:level="1"><nlm:affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</nlm:affiliation>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Uzhgorod National University, Uzhgorod</wicri:regionArea>
<wicri:noRegion>Uzhgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, Emily" sort="Chan, Emily" uniqKey="Chan E" first="Emily" last="Chan">Emily Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vanderbilt University Medical Center, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lordick, Florian" sort="Lordick, Florian" uniqKey="Lordick F" first="Florian" last="Lordick">Florian Lordick</name>
<affiliation wicri:level="3"><nlm:affiliation>University Cancer Center, Leipzig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University Cancer Center, Leipzig</wicri:regionArea>
<placeName><region type="land" nuts="1">Saxe (Land)</region>
<region type="district" nuts="2">District de Leipzig</region>
<settlement type="city">Leipzig</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J A" last="Punt">Cornelis J A. Punt</name>
<affiliation wicri:level="3"><nlm:affiliation>Academic Medical Center, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strickland, Andrew H" sort="Strickland, Andrew H" uniqKey="Strickland A" first="Andrew H" last="Strickland">Andrew H. Strickland</name>
<affiliation wicri:level="1"><nlm:affiliation>Monash Medical Center, East Bentleigh, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Monash Medical Center, East Bentleigh</wicri:regionArea>
<wicri:noRegion>East Bentleigh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, Gregory" sort="Wilson, Gregory" uniqKey="Wilson G" first="Gregory" last="Wilson">Gregory Wilson</name>
<affiliation wicri:level="3"><nlm:affiliation>Christie Hospital, Manchester, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Christie Hospital, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ciuleanu, Tudor E" sort="Ciuleanu, Tudor E" uniqKey="Ciuleanu T" first="Tudor E" last="Ciuleanu">Tudor E. Ciuleanu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca</wicri:regionArea>
<wicri:noRegion>Cluj Napoca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Roman, Laslo" sort="Roman, Laslo" uniqKey="Roman L" first="Laslo" last="Roman">Laslo Roman</name>
<affiliation wicri:level="1"><nlm:affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Leningrad Regional Oncology Dispensary, Saint Petersburg</wicri:regionArea>
<wicri:noRegion>Saint Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals and KU Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="He, Pei" sort="He, Pei" uniqKey="He P" first="Pei" last="He">Pei He</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Hua" sort="Yu, Hua" uniqKey="Yu H" first="Hua" last="Yu">Hua Yu</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koukakis, Reija" sort="Koukakis, Reija" uniqKey="Koukakis R" first="Reija" last="Koukakis">Reija Koukakis</name>
<affiliation wicri:level="1"><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea>
<wicri:noRegion>Zug</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Terwey, Jan Henrik" sort="Terwey, Jan Henrik" uniqKey="Terwey J" first="Jan-Henrik" last="Terwey">Jan-Henrik Terwey</name>
<affiliation wicri:level="1"><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea>
<wicri:noRegion>Zug</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jung, Andre S" sort="Jung, Andre S" uniqKey="Jung A" first="Andre S" last="Jung">Andre S. Jung</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sidhu, Roger" sort="Sidhu, Roger" uniqKey="Sidhu R" first="Roger" last="Sidhu">Roger Sidhu</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patterson, Scott D" sort="Patterson, Scott D" uniqKey="Patterson S" first="Scott D" last="Patterson">Scott D. Patterson</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc., Thousand Oaks, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Camptothecin (adverse effects)</term>
<term>Camptothecin (analogs & derivatives)</term>
<term>Camptothecin (therapeutic use)</term>
<term>Colorectal Neoplasms (drug therapy)</term>
<term>Colorectal Neoplasms (genetics)</term>
<term>Colorectal Neoplasms (mortality)</term>
<term>Colorectal Neoplasms (pathology)</term>
<term>DNA Mutational Analysis</term>
<term>Exons</term>
<term>Female</term>
<term>Fluorouracil (adverse effects)</term>
<term>Fluorouracil (therapeutic use)</term>
<term>Genes, ras</term>
<term>Humans</term>
<term>Leucovorin (adverse effects)</term>
<term>Leucovorin (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Metastasis</term>
<term>Proportional Hazards Models</term>
<term>Proto-Oncogene Proteins B-raf (genetics)</term>
<term>Retreatment</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de mutations d'ADN</term>
<term>Analyse de survie</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Camptothécine (analogues et dérivés)</term>
<term>Camptothécine (effets indésirables)</term>
<term>Camptothécine (usage thérapeutique)</term>
<term>Exons</term>
<term>Femelle</term>
<term>Fluorouracil (effets indésirables)</term>
<term>Fluorouracil (usage thérapeutique)</term>
<term>Gènes ras</term>
<term>Humains</term>
<term>Leucovorine (effets indésirables)</term>
<term>Leucovorine (usage thérapeutique)</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Protéines proto-oncogènes B-raf (génétique)</term>
<term>Reprise du traitement</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tumeurs colorectales (anatomopathologie)</term>
<term>Tumeurs colorectales (génétique)</term>
<term>Tumeurs colorectales (mortalité)</term>
<term>Tumeurs colorectales (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Camptothecin</term>
<term>Fluorouracil</term>
<term>Leucovorin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Camptothecin</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Camptothécine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colorectal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Camptothécine</term>
<term>Fluorouracil</term>
<term>Leucovorine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Colorectal Neoplasms</term>
<term>Proto-Oncogene Proteins B-raf</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines proto-oncogènes B-raf</term>
<term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Colorectal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Camptothecin</term>
<term>Fluorouracil</term>
<term>Leucovorin</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Camptothécine</term>
<term>Fluorouracil</term>
<term>Leucovorine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>DNA Mutational Analysis</term>
<term>Exons</term>
<term>Female</term>
<term>Genes, ras</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Metastasis</term>
<term>Proportional Hazards Models</term>
<term>Retreatment</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de mutations d'ADN</term>
<term>Analyse de survie</term>
<term>Exons</term>
<term>Femelle</term>
<term>Gènes ras</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Reprise du traitement</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26341920</PMID>
<DateCreated><Year>2015</Year>
<Month>12</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>03</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>24</Issue>
<PubDate><Year>2015</Year>
<Month>12</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
<ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</ArticleTitle>
<Pagination><MedlinePgn>5469-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-0526</ELocationID>
<Abstract><AbstractText Label="PURPOSE">We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).</AbstractText>
<AbstractText Label="EXPERIMENTAL DESIGN">Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) were coprimary endpoints.</AbstractText>
<AbstractText Label="RESULTS">The RAS ascertainment rate was 85%; 18% of wild-type KRAS exon 2 tumors harbored other RAS mutations. For PFS and OS, the hazard ratio (HR) for panitumumab plus FOLFIRI versus FOLFIRI alone more strongly favored panitumumab in the wild-type RAS population than in the wild-type KRAS exon 2 population [PFS HR, 0.70 (95% confidence interval [CI], 0.54-0.91); P = 0.007 vs. 0.73 (95% CI, 0.59-0.90); P = 0.004; OS HR, 0.81 (95% CI, 0.63-1.03); P = 0.08 vs. 0.85 (95% CI, 0.70-1.04); P = 0.12]. Patients with RAS mutations were unlikely to benefit from panitumumab. Among RAS wild-type patients, the objective response rate was 41% in the panitumumab-FOLFIRI group versus 10% in the FOLFIRI group.</AbstractText>
<AbstractText Label="CONCLUSIONS">Patients with RAS mutations were unlikely to benefit from panitumumab-FOLFIRI and the benefit-risk of panitumumab-FOLFIRI was improved in the wild-type RAS population compared with the wild-type KRAS exon 2 population. These findings support RAS testing for patients with mCRC. Clin Cancer Res; 21(24); 5469-79. ©2015 AACR.See related commentary by Salazar and Ciardiello, p. 5415.</AbstractText>
<CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peeters</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oliner</LastName>
<ForeName>Kelly S</ForeName>
<Initials>KS</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Price</LastName>
<ForeName>Timothy J</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo><Affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cervantes</LastName>
<ForeName>Andrés</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sobrero</LastName>
<ForeName>Alberto F</ForeName>
<Initials>AF</Initials>
<AffiliationInfo><Affiliation>Ospedale San Martino, Genova, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ducreux</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hotko</LastName>
<ForeName>Yevhen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>André</LastName>
<ForeName>Thierry</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Emily</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lordick</LastName>
<ForeName>Florian</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>University Cancer Center, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Punt</LastName>
<ForeName>Cornelis J A</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Academic Medical Center, Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strickland</LastName>
<ForeName>Andrew H</ForeName>
<Initials>AH</Initials>
<AffiliationInfo><Affiliation>Monash Medical Center, East Bentleigh, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wilson</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Christie Hospital, Manchester, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ciuleanu</LastName>
<ForeName>Tudor E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo><Affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roman</LastName>
<ForeName>Laslo</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Cutsem</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Pei</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Hua</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Koukakis</LastName>
<ForeName>Reija</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Terwey</LastName>
<ForeName>Jan-Henrik</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jung</LastName>
<ForeName>Andre S</ForeName>
<Initials>AS</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sidhu</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patterson</LastName>
<ForeName>Scott D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00339183</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Cancer Res</MedlineTA>
<NlmUniqueID>9502500</NlmUniqueID>
<ISSNLinking>1078-0432</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6A901E312A</RegistryNumber>
<NameOfSubstance UI="C500592">panitumumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber>
<NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>XT3Z54Z28A</RegistryNumber>
<NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C480833">IFL protocol</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Cancer Res. 2015 Dec 15;21(24):5415-6</RefSource>
<PMID Version="1">26463710</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011905" MajorTopicYN="Y">Genes, ras</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>03</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>06</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>9</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>9</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26341920</ArticleId>
<ArticleId IdType="pii">1078-0432.CCR-15-0526</ArticleId>
<ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0526</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Roumanie</li>
<li>Royaume-Uni</li>
<li>Russie</li>
<li>Suisse</li>
<li>Ukraine</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Californie</li>
<li>District de Leipzig</li>
<li>Grand Manchester</li>
<li>Hollande-Septentrionale</li>
<li>Saxe (Land)</li>
<li>Tennessee</li>
<li>Île-de-France</li>
</region>
<settlement><li>Amsterdam</li>
<li>Leipzig</li>
<li>Manchester</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="Belgique"><noRegion><name sortKey="Peeters, Marc" sort="Peeters, Marc" uniqKey="Peeters M" first="Marc" last="Peeters">Marc Peeters</name>
</noRegion>
<name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Oliner, Kelly S" sort="Oliner, Kelly S" uniqKey="Oliner K" first="Kelly S" last="Oliner">Kelly S. Oliner</name>
</region>
<name sortKey="Chan, Emily" sort="Chan, Emily" uniqKey="Chan E" first="Emily" last="Chan">Emily Chan</name>
<name sortKey="He, Pei" sort="He, Pei" uniqKey="He P" first="Pei" last="He">Pei He</name>
<name sortKey="Jung, Andre S" sort="Jung, Andre S" uniqKey="Jung A" first="Andre S" last="Jung">Andre S. Jung</name>
<name sortKey="Patterson, Scott D" sort="Patterson, Scott D" uniqKey="Patterson S" first="Scott D" last="Patterson">Scott D. Patterson</name>
<name sortKey="Sidhu, Roger" sort="Sidhu, Roger" uniqKey="Sidhu R" first="Roger" last="Sidhu">Roger Sidhu</name>
<name sortKey="Yu, Hua" sort="Yu, Hua" uniqKey="Yu H" first="Hua" last="Yu">Hua Yu</name>
</country>
<country name="Australie"><noRegion><name sortKey="Price, Timothy J" sort="Price, Timothy J" uniqKey="Price T" first="Timothy J" last="Price">Timothy J. Price</name>
</noRegion>
<name sortKey="Strickland, Andrew H" sort="Strickland, Andrew H" uniqKey="Strickland A" first="Andrew H" last="Strickland">Andrew H. Strickland</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Cervantes, Andres" sort="Cervantes, Andres" uniqKey="Cervantes A" first="Andrés" last="Cervantes">Andrés Cervantes</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Sobrero, Alberto F" sort="Sobrero, Alberto F" uniqKey="Sobrero A" first="Alberto F" last="Sobrero">Alberto F. Sobrero</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Ducreux, Michel" sort="Ducreux, Michel" uniqKey="Ducreux M" first="Michel" last="Ducreux">Michel Ducreux</name>
</region>
<name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name>
</country>
<country name="Ukraine"><noRegion><name sortKey="Hotko, Yevhen" sort="Hotko, Yevhen" uniqKey="Hotko Y" first="Yevhen" last="Hotko">Yevhen Hotko</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Saxe (Land)"><name sortKey="Lordick, Florian" sort="Lordick, Florian" uniqKey="Lordick F" first="Florian" last="Lordick">Florian Lordick</name>
</region>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J A" last="Punt">Cornelis J A. Punt</name>
</region>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Wilson, Gregory" sort="Wilson, Gregory" uniqKey="Wilson G" first="Gregory" last="Wilson">Gregory Wilson</name>
</region>
</country>
<country name="Roumanie"><noRegion><name sortKey="Ciuleanu, Tudor E" sort="Ciuleanu, Tudor E" uniqKey="Ciuleanu T" first="Tudor E" last="Ciuleanu">Tudor E. Ciuleanu</name>
</noRegion>
</country>
<country name="Russie"><noRegion><name sortKey="Roman, Laslo" sort="Roman, Laslo" uniqKey="Roman L" first="Laslo" last="Roman">Laslo Roman</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Koukakis, Reija" sort="Koukakis, Reija" uniqKey="Koukakis R" first="Reija" last="Koukakis">Reija Koukakis</name>
</noRegion>
<name sortKey="Terwey, Jan Henrik" sort="Terwey, Jan Henrik" uniqKey="Terwey J" first="Jan-Henrik" last="Terwey">Jan-Henrik Terwey</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002F44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:26341920 |texte= Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26341920" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |